Is GHK-Cu FDA-approved?

No. No GHK-Cu product is FDA-approved for any indication, and the FDA has not approved GHK-Cu for hair loss or any form of alopecia. FDA placed GHK-Cu for injectable routes of administration in category 2 of its 503A bulk substances policy, meaning the agency identified significant safety risks for the injectable form, and the nomination was withdrawn in April 2026. Topical preparations a compounding pharmacy prepares to prescription are compounded products that have not been evaluated by the FDA.

Does the FDA entry for injectable GHK-Cu apply to the topical scalp solution?

The entry reads GHK-Cu for injectable routes of administration; FDA placed it in category 2 and the nomination was withdrawn in April 2026, and the rationale concerns immunogenicity risk from aggregation and peptide-related impurities in an injectable preparation. A topical scalp solution or cream is a compounded prescription product prepared by a licensed 503A pharmacy under its state board’s oversight, and it is not an approved product. ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance.

What does the GHK-Cu literature actually cover?

Mostly skin, wounds and gene expression. The 2015 and 2018 reviews by Pickart and colleagues summarise in vitro gene-expression work, animal wound models and cosmetic-formulation studies in human skin. The animal studies cited on this page examined an irradiated rat wound model in 2013 and a rat ligament model in 2015. The hair literature is small and concerns a related peptide, AHK-Cu, in follicle organ culture.

Is there a human trial of GHK-Cu for hair?

No randomised controlled trial of GHK-Cu in human pattern hair loss has been published as of this review. The follicle organ-culture study most often cited for copper peptides used AHK-Cu, a structural relative, and the animal work is a 1993 primate model of copper-binding peptides as a class. The hair cluster page on GHK-Cu takes that literature in detail.

Why does a copper peptide get paired with microneedling?

Because a hydrophilic tripeptide-copper complex does not cross intact stratum corneum readily, and a 2015 study in Pharmaceutical Research examined microneedle-mediated delivery of copper peptide through skin. That is a delivery question rather than an efficacy finding, and the clinic-launch guide on topical application and microneedling on this site explains what a cleared microneedling device is and is not cleared to do.

Evidence summary

GHK-Cu: Chemistry, Literature, and the Injectable Qualifier

Limited human dataFDA 503A nomination withdrawn9 peer-reviewed sources

Case reports or small series only. No controlled trial of meaningful size.

GHK-Cu is the tripeptide glycyl-histidyl-lysine complexed with copper, one of the most written-about peptides in skin science and one of the most loosely cited. Its literature is large and mostly concerns skin, wounds and gene expression; its hair literature is small and concerns a related molecule; and its regulatory position depends on the route, because FDA’s entry covers the injectable form, placed in category 2 of its 503A bulk substances policy and withdrawn by the nominator in April 2026, while the topical preparations are compounded prescription products prepared by a licensed 503A pharmacy under its state board’s oversight.

This page separates those three things. It is an evidence summary rather than a product page. ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance; the topical scalp solution and the creams a 503A pharmacy prepares to prescription are listed on the product pages linked below by composition and dating only.

Also known as: copper tripeptide, glycyl-histidyl-lysine copper, GHK copper complex, copper peptide.

A tripeptide with a copper-binding motif

GHK is a naturally occurring tripeptide, glycine, histidine and lysine in that order, first isolated from human plasma in the 1970s and found since in saliva and urine. The free peptide has a mass of roughly 340 daltons, and its histidine and the terminal amine give it a high affinity for copper(II), so that in tissue it exists largely as the copper complex written GHK-Cu.

Plasma concentrations of the peptide have been reported to fall with age, an observation the 2015 review by Pickart and colleagues in BioMed Research International uses to frame the peptide as a natural modulator of skin repair. Whether that decline is cause or correlate is not settled by the observation, and the review is careful to present it as the motivation for the research rather than as a finding about ageing.

Sequence: glycyl-histidyl-lysine, three residues, roughly 340 daltons as the free peptide.
Copper complex: GHK binds copper(II) with high affinity and is studied almost entirely as the complex.
Origin: isolated from human plasma; also present in saliva and urine.
Related molecule: AHK-Cu, alanyl-histidyl-lysine with copper, shares the binding motif and is the peptide in the most-cited follicle study.

What the literature describes it doing

The 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences is the standard entry point. It summarises gene-expression work in which GHK was reported to change the expression of a large fraction of human genes in cultured cells, and it collects the in vitro and animal literature described in the context of collagen and glycosaminoglycan synthesis, angiogenesis, anti-inflammatory signalling and wound models. The review is a synthesis by the peptide’s principal investigator, which is a reason to read it and a reason to read the primary studies it cites.

The animal work is where mechanism meets a measurable outcome. A 2013 study in Otolaryngology, Head and Neck Surgery examined a topical copper tripeptide complex in an irradiated rat wound model, and a 2015 study in the Journal of Orthopaedic Research examined GHK-Cu in a rat model of anterior cruciate ligament reconstruction and reported a transient effect on healing outcome. Both are preclinical, both are cited below with that design labelled, and neither concerns hair.

Delivery is its own research question, because a hydrophilic tripeptide-copper complex does not cross intact stratum corneum readily. A 2015 study in Pharmaceutical Research examined microneedle-mediated delivery of copper peptide through skin, which is the mechanistic background to the pairing of copper peptide formulations with microneedling in aesthetic practice.

How far the evidence has got

For skin, the human evidence consists of cosmetic-formulation studies summarised in the reviews, most of them older than this page’s source window and several of them unpublished in indexed journals. For wounds, there are animal models and older human wound series described in the same reviews. For hair, there is no randomised controlled trial of GHK-Cu in human pattern hair loss, and the follicle organ-culture study most often cited used AHK-Cu rather than GHK-Cu; the hair cluster page linked below takes that literature at its own level of detail.

The evidence state on this page is therefore recorded as limited human data. That is a description of the literature, and it is stated once here rather than hedged in every sentence.

Gene-expression and in vitro work: substantial, synthesised in the 2015 and 2018 reviews.
Animal models: wound and ligament studies from 2013 and 2015, preclinical.
Human skin studies: cosmetic-formulation work summarised in the reviews.
Human hair trials: none published for GHK-Cu.

Regulatory position: the route decides

FDA placed GHK-Cu for injectable routes of administration in category 2 of its interim policy on bulk drug substances for compounding under section 503A, meaning the agency identified significant safety risks, and the nomination was withdrawn by the nominator in April 2026. FDA now carries the substance under nominations withdrawn and still publishes the rationale it wrote, and a withdrawn nomination leaves the substance on no 503A list for any route. The entry is written for injectable routes, and what it does or does not establish for a topical scalp solution or a cream is a determination for the compounding pharmacy under its state board’s oversight, which this page does not make. This is FDA’s stated rationale in full:

FDA, on GHK-Cu for injectable routes of administration

“Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.”

FDA source , checked 2026-09-16

Aggregation and peptide-related impurities are properties of a preparation rather than of the sequence, which is why the agency’s concern attaches to characterisation of an injectable product rather than to the molecule in the abstract. No GHK-Cu product is FDA-approved for any indication, and the FDA has not approved GHK-Cu for hair loss or any form of alopecia. Topical preparations prepared under section 503A are compounded prescription products that have not been evaluated by the FDA for safety, effectiveness or quality. FDA revises the list; the access date is shown with the quotation above.

Common questions

Is GHK-Cu FDA-approved?: No. No GHK-Cu product is FDA-approved for any indication, and the FDA has not approved GHK-Cu for hair loss or any form of alopecia. FDA placed GHK-Cu for injectable routes of administration in category 2 of its 503A bulk substances policy, meaning the agency identified significant safety risks for the injectable form, and the nomination was withdrawn in April 2026. Topical preparations a compounding pharmacy prepares to prescription are compounded products that have not been evaluated by the FDA.
Does the FDA entry for injectable GHK-Cu apply to the topical scalp solution?: The entry reads GHK-Cu for injectable routes of administration; FDA placed it in category 2 and the nomination was withdrawn in April 2026, and the rationale concerns immunogenicity risk from aggregation and peptide-related impurities in an injectable preparation. A topical scalp solution or cream is a compounded prescription product prepared by a licensed 503A pharmacy under its state board’s oversight, and it is not an approved product. ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance.
What does the GHK-Cu literature actually cover?: Mostly skin, wounds and gene expression. The 2015 and 2018 reviews by Pickart and colleagues summarise in vitro gene-expression work, animal wound models and cosmetic-formulation studies in human skin. The animal studies cited on this page examined an irradiated rat wound model in 2013 and a rat ligament model in 2015. The hair literature is small and concerns a related peptide, AHK-Cu, in follicle organ culture.
Is there a human trial of GHK-Cu for hair?: No randomised controlled trial of GHK-Cu in human pattern hair loss has been published as of this review. The follicle organ-culture study most often cited for copper peptides used AHK-Cu, a structural relative, and the animal work is a 1993 primate model of copper-binding peptides as a class. The hair cluster page on GHK-Cu takes that literature in detail.
Why does a copper peptide get paired with microneedling?: Because a hydrophilic tripeptide-copper complex does not cross intact stratum corneum readily, and a 2015 study in Pharmaceutical Research examined microneedle-mediated delivery of copper peptide through skin. That is a delivery question rather than an efficacy finding, and the clinic-launch guide on topical application and microneedling on this site explains what a cleared microneedling device is and is not cleared to do.

Sources

Every source is peer-reviewed and published within the last fifteen years. Each line states what that source is carrying, so nothing is here to pad a count.

Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018.PMID 29986520
Narrative review
Source 1 supports: The standard review of the GHK-Cu literature, cited for the gene-expression synthesis and the scope of the wound and skin work.
Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015.PMID 26236730
Narrative review
Source 2 supports: The earlier review, cited for the plasma-decline observation and for its summary of the cosmetic-formulation studies in human skin.
Journal of Orthopaedic Research, 2015. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. Journal of Orthopaedic Research. 2015.PMID 25731775
Preclinical
Source 3 supports: An animal model in which GHK-Cu itself was studied and a measurable, transient outcome was reported; cited as representative preclinical evidence.
Otolaryngology, Head and Neck Surgery, 2013. Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. Otolaryngology, Head and Neck Surgery. 2013.PMID 23744835
Preclinical
Source 4 supports: The irradiated-wound animal model, cited for the topical route and for the preclinical design that most of the wound literature shares.
Pharmaceutical Research, 2015. Microneedle-mediated delivery of copper peptide through skin. Pharmaceutical Research. 2015.PMID 25690343
In vitro
Source 5 supports: The delivery study, cited for why a hydrophilic copper peptide is paired with microneedling in practice.
Campbell JD, McDonough JE, Zeskind JE, et al.. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012.PMID 22937864
In vitro
Source 6 supports: The gene-expression signature study behind the claim of broad transcriptional effects, cited so a reader can see it was a lung-tissue study.
Mokhtar J, Mohamad B, Haddad J, et al.. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthetic Surgery Journal. 2026.PMID 42619529
Narrative review
Source 7 supports: The most recent review of GHK-Cu in aesthetic practice, cited for the current framing of the peptide and its account of the evidence.
Ogorek K, Nowak K, Wadych E, et al.. Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes?. Molecules. 2025.PMID 39795193
Narrative review
Source 8 supports: A review of permeation methods for liposomal GHK-Cu, cited for the delivery question any topical formulation has to answer.
Hu J, Zhang C, Wang F, et al.. Glycyl-L-histidyl-L-lysine-Cu2+ (GHK-Cu) attenuates CuSO4 or LPS induced-inflammation in zebrafish larvae model. European Journal of Pharmacology. 2026.PMID 41997403
Preclinical
Source 9 supports: The most recent preclinical work on the anti-inflammatory signalling the reviews describe, in a zebrafish model.

Reviewed 2026-09-15 by Benn Bluestein-Veyra, M.Sc. Organic Chemistry. This page is an evidence summary, not medical advice, and not an offer to sell. ExaVeyra does not supply GHK-Cu. Compounded medications are not FDA-approved finished drug products.